• search

Aurobindo Pharma gets license from BMS for two ARV products

Written by: Staff

Mumbai, Mar 17 (UNI) Aurobindo Pharma has announced that it has been given the license to market Stavudine and Didanosine, two important antiretrovirals (ARV) by Bristol-Myers Squibb company.

Announcing this to BSE today, the company said one of the objectives of this license is to increase access of the products for the benefit of the people in the aforesaid territory specifically for the treatment of HIV/AIDS.

The company has the largest number of approved products by US Food and Drug Administration (FDA) for the ARV segment and continues to play an anchor role in the management of AIDS by supply APIs anf formulations for most of the antiretrovirals.


For Daily Alerts
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more